{"transactions":[{"id":2315411,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":128686,"kind":"person","name":"Dalgleish Scott","position":1,"cik":"0001891053","reported_name":"Dalgleish Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-30T00:10:43.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":162891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as to 1/3rd of the options granted on the second anniversary of November 12, 2021 (the \"Vesting Commencement Date\"), with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":162891,"derivative":{"exercise_price":7.09,"expiration_date":"2032-03-21","underlying":"Common stock","underlying_shares":162891},"source":{"system":"sec-edgar","filing":"0001628280-22-007760","document":"wf-form4a_164859902956940.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007760/wf-form4a_164859902956940.xml","form_type":"4/A","original_submission_date":"2022-03-23"}},{"id":2320140,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":128686,"kind":"person","name":"Dalgleish Scott","position":1,"cik":"0001891053","reported_name":"Dalgleish Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T23:37:35.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":26062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as to 1/3rd of the options granted on the second anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":26062,"derivative":{"exercise_price":7.09,"expiration_date":"2032-03-21","underlying":"Common stock","underlying_shares":26062},"source":{"system":"sec-edgar","filing":"0001628280-22-007103","document":"wf-form4_164807863846129.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007103/wf-form4_164807863846129.xml","form_type":"4"}},{"id":2320139,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":128686,"kind":"person","name":"Dalgleish Scott","position":1,"cik":"0001891053","reported_name":"Dalgleish Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-03-23T23:37:35.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":32092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of November 12, 2021 (\"the Vesting Commencement Date\"), with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of November 12, 2021 (\"the Vesting Commencement Date\"), with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":151008,"source":{"system":"sec-edgar","filing":"0001628280-22-007103","document":"wf-form4_164807863846129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007103/wf-form4_164807863846129.xml","form_type":"4"}},{"id":2510851,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":128686,"kind":"person","name":"Dalgleish Scott","position":1,"cik":"0001891053","reported_name":"Dalgleish Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2021-11-17T02:56:29.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":350876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement.These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement.These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date."}],"balance_after":350876,"derivative":{"exercise_price":0.86,"expiration_date":"2030-11-16","underlying":"Common Stock","underlying_shares":350876},"source":{"system":"sec-edgar","filing":"0001104659-21-140226","document":"tm2132979d17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140226/tm2132979d17_4seq1.xml","form_type":"4"}},{"id":2510850,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":128686,"kind":"person","name":"Dalgleish Scott","position":1,"cik":"0001891053","reported_name":"Dalgleish Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2021-11-17T02:56:29.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":261023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the \"Original Grant Date\"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the \"Original Grant Date\"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."}],"balance_after":261023,"derivative":{"exercise_price":0.86,"expiration_date":"2030-11-16","underlying":"Common Stock","underlying_shares":261023},"source":{"system":"sec-edgar","filing":"0001104659-21-140226","document":"tm2132979d17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140226/tm2132979d17_4seq1.xml","form_type":"4"}},{"id":2510849,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":128686,"kind":"person","name":"Dalgleish Scott","position":1,"cik":"0001891053","reported_name":"Dalgleish Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-17T02:56:29.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":71350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as June 28, 2021, by and among  DFP Healthcare Acqusitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"The shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":118916,"source":{"system":"sec-edgar","filing":"0001104659-21-140226","document":"tm2132979d17_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140226/tm2132979d17_4seq1.xml","form_type":"4"}},{"id":2510848,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":128686,"kind":"person","name":"Dalgleish Scott","position":1,"cik":"0001891053","reported_name":"Dalgleish Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-17T02:56:29.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":47566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as June 28, 2021, by and among  DFP Healthcare Acqusitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":47566,"source":{"system":"sec-edgar","filing":"0001104659-21-140226","document":"tm2132979d17_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140226/tm2132979d17_4seq1.xml","form_type":"4"}}]}